Can you take Quizartinib with Twynsta?

The telmisartan in Twynsta has a major potential interaction with Angioedema.

The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema. Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists. Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician. Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx. Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.

The amLODIPine in Twynsta has a major potential interaction with Aortic Stenosis.

In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock. Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients. The use of verapamil and diltiazem is specifically contraindicated under these circumstances.

The telmisartan in Twynsta has a moderate potential interaction with Biliary Obstruction.

Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine. Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision. Patients with hepatic impairment or biliary obstruction may require a dosage adjustment. The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.

The amLODIPine in Twynsta has a major potential interaction with Cardiogenic Shock.

In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock. Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients. The use of verapamil and diltiazem is specifically contraindicated under these circumstances.

The telmisartan in Twynsta has a major potential interaction with Dehydration.

Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients. Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients). Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable. Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.

The telmisartan in Twynsta has a major potential interaction with Diabetes Mellitus.

The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.

The amLODIPine in Twynsta has a moderate potential interaction with Heart Attack.

Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect. Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil. Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction. Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker. Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.

Quizartinib has a major potential interaction with Heart Disease.

Quizartinib prolongs the QT interval in a dose and concentration dependent manner. Due to the serious risk of QTc prolongation, quizartinib is contraindicated in patients with long QT syndrome, a history of ventricular arrhythmias or torsades de points, severe hypokalemia, or severe hypomagnesemia. Additionally, avoid use in patients who are at significant risk of developing torsades de pointes, including uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, tachyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Perform an ECG and correct electrolyte abnormalities before and during treatment as indicated, especially in high-risk patients or during concomitant use with strong CYP450 3A4 inhibitors or drugs known to prolong the QT interval. Do not initiate or escalate therapy in patients with QTcF interval greater than 450 ms; dose adjustments based on QTcF interval may be required.

The telmisartan in Twynsta has a moderate potential interaction with Heart Failure.

Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system. In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion. In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death. Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion. In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated. Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.

The amLODIPine in Twynsta has a moderate potential interaction with Heart Failure.

Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect. Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil. Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction. Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker. Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.

The telmisartan in Twynsta has a major potential interaction with Hemodialysis.

Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients. Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients). Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable. Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.

Quizartinib has a major potential interaction with High Blood Pressure.

Quizartinib prolongs the QT interval in a dose and concentration dependent manner. Due to the serious risk of QTc prolongation, quizartinib is contraindicated in patients with long QT syndrome, a history of ventricular arrhythmias or torsades de points, severe hypokalemia, or severe hypomagnesemia. Additionally, avoid use in patients who are at significant risk of developing torsades de pointes, including uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, tachyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Perform an ECG and correct electrolyte abnormalities before and during treatment as indicated, especially in high-risk patients or during concomitant use with strong CYP450 3A4 inhibitors or drugs known to prolong the QT interval. Do not initiate or escalate therapy in patients with QTcF interval greater than 450 ms; dose adjustments based on QTcF interval may be required.

The telmisartan in Twynsta has a moderate potential interaction with Hyperkalemia.

Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia. Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia. Use caution when using these agents together and monitor serum potassium periodically.

Quizartinib has a major potential interaction with Hypokalemia.

Quizartinib prolongs the QT interval in a dose and concentration dependent manner. Due to the serious risk of QTc prolongation, quizartinib is contraindicated in patients with long QT syndrome, a history of ventricular arrhythmias or torsades de points, severe hypokalemia, or severe hypomagnesemia. Additionally, avoid use in patients who are at significant risk of developing torsades de pointes, including uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, tachyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Perform an ECG and correct electrolyte abnormalities before and during treatment as indicated, especially in high-risk patients or during concomitant use with strong CYP450 3A4 inhibitors or drugs known to prolong the QT interval. Do not initiate or escalate therapy in patients with QTcF interval greater than 450 ms; dose adjustments based on QTcF interval may be required.

The telmisartan in Twynsta has a major potential interaction with Hyponatremia.

Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients. Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients). Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable. Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.

The amLODIPine in Twynsta has a major potential interaction with Hypotension.

In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock. Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients. The use of verapamil and diltiazem is specifically contraindicated under these circumstances.

The amLODIPine in Twynsta has a major potential interaction with Ischemic Heart Disease.

Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations. The mechanism of this effect is not established. Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.

The amLODIPine in Twynsta has a major potential interaction with Liver Disease.

Calcium channel blockers (CCBs) are extensively metabolized by the liver. The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation. In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin. While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury. Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function. Periodic monitoring of liver function is advised.

Quizartinib has a moderate potential interaction with Liver Disease.

Midostaurin and quizartinib should be used with caution in patients with severe hepatic or severe renal dysfunction as the pharmacokinetics of these agents have not been studied in these patients. No dosage adjustments are recommended in patients with mild or moderate hepatic or renal dysfunction.

The telmisartan in Twynsta has a moderate potential interaction with Liver Disease.

Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine. Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision. Patients with hepatic impairment or biliary obstruction may require a dosage adjustment. The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.

Quizartinib has a major potential interaction with Magnesium Imbalance.

Quizartinib prolongs the QT interval in a dose and concentration dependent manner. Due to the serious risk of QTc prolongation, quizartinib is contraindicated in patients with long QT syndrome, a history of ventricular arrhythmias or torsades de points, severe hypokalemia, or severe hypomagnesemia. Additionally, avoid use in patients who are at significant risk of developing torsades de pointes, including uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, tachyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Perform an ECG and correct electrolyte abnormalities before and during treatment as indicated, especially in high-risk patients or during concomitant use with strong CYP450 3A4 inhibitors or drugs known to prolong the QT interval. Do not initiate or escalate therapy in patients with QTcF interval greater than 450 ms; dose adjustments based on QTcF interval may be required.

Quizartinib has a moderate potential interaction with Renal Dysfunction.

Midostaurin and quizartinib should be used with caution in patients with severe hepatic or severe renal dysfunction as the pharmacokinetics of these agents have not been studied in these patients. No dosage adjustments are recommended in patients with mild or moderate hepatic or renal dysfunction.

The telmisartan in Twynsta has a moderate potential interaction with Renal Dysfunction.

Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents. Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.

The telmisartan in Twynsta has a moderate potential interaction with Renal Dysfunction.

Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine. Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision. Patients with hepatic impairment or biliary obstruction may require a dosage adjustment. The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.

Quizartinib has a major potential interaction with Underactive Thyroid.

Quizartinib prolongs the QT interval in a dose and concentration dependent manner. Due to the serious risk of QTc prolongation, quizartinib is contraindicated in patients with long QT syndrome, a history of ventricular arrhythmias or torsades de points, severe hypokalemia, or severe hypomagnesemia. Additionally, avoid use in patients who are at significant risk of developing torsades de pointes, including uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, tachyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Perform an ECG and correct electrolyte abnormalities before and during treatment as indicated, especially in high-risk patients or during concomitant use with strong CYP450 3A4 inhibitors or drugs known to prolong the QT interval. Do not initiate or escalate therapy in patients with QTcF interval greater than 450 ms; dose adjustments based on QTcF interval may be required.